Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
10.1016/0361-9230(96)00172-4 53 DateY.MurakamiN.ToshinaiK.MatsukuraS.NiijimaA.MatsuoH.et al
Lee and staff
The fate of new fosfamides in phase iii studies in advanced soft tissue sarcoma
This was Citius second try for FDA approval, after the regulator rejected Lymphir in July 2023, outlining the need for enhanced product resting requirements. In its resubmitted data package, the company included findings from the from the Phase III Study 302 trial, where treatment with the drug led to an objective response rate of 36.2%, with 8.7% reaching complete response
MOTS-c, like most of the peptides we offer, is a delicate chain of amino acids
US$ 20.54
US$ 23.79
US$ 29.15
